Pegcetacoplan: A New Opportunity for Complement Inhibition in PNH
Ilene C. Weitz
Abstract
Pegcetacoplan is the newest inhibitor of the complement system to be approved by the FDA and EMA for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). The cyclic peptide inhibitor of C3 was evaluated in several clinical trials in PHN leading to its approval. The focus of this paper will review the efficacy and safety of Pegcetacoplan (PEG), and considerations for use in patients with PNH.
Topics & Concepts
MedicineParoxysmal nocturnal hemoglobinuriaEculizumabClinical trialComplement (music)CD59Intensive care medicineInternal medicineImmunologyComplement systemAntibodyGenePhenotypeChemistryComplementationBiochemistryComplement system in diseasesBlood groups and transfusionLiver Disease and Transplantation